Brain potentials and attention after acute and subchronic intranasal administration of ACTH 4-10 and desacetyl-α-MSH in humans

Neuroendocrinology

Volumn 70, Issue 1, 1999, Pages 63-72

  Smolnik, Rüdiger ^a   Mölle, Matthias ^b   Fehm, Horst Lorenz ^b   Born, Jan ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b NONE

Author keywords

ACTH 4 10; Clinical neuroendocrinology; Corticotropin; Electrophysiology; Melanostimulating hormone; Mood

Indexed keywords

CORTICOTROPIN[4-10]; INTERMEDIN; MELANOCORTIN RECEPTOR;

ADULT; ARTICLE; AUDITORY STIMULATION; BRAIN CORTEX; BRAIN FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EVENT RELATED POTENTIAL; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELECTIVE ATTENTION;

ADMINISTRATION, INTRANASAL; ADRENOCORTICOTROPIC HORMONE; ADULT; ALPHA-MSH; ATTENTION; BLOOD PRESSURE; BRAIN; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; FEMALE; HEART RATE; HUMANS; HYDROCORTISONE; MALE; MOTIVATION; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS;

EID: 0032786573     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054460     Document Type: Article

References (46)

1. De Wied D: Neurotrophic effects of ACTH/ MSH neuropeptides. Acta Neurobiol Exp (Warsz) 1990;50:353-366.
2. Beckwith BE, Sandman CA: Central nervous system and peripheral effects of ACTH, MSH, and related neuropeptides. Peptides 1982;3: 411-420.
3. Born J, Fehm HL, Voigt KH: ACTH and attention in humans: A review. Neuropsychobiology 1986;15:165-186.
4. Born J, Bräuninger W, Fehm-Wolfsdorf G, Voigt KH, Pauschinger P, Fehm HL: Dose-dependent influences on electrophysiological signs of attention in humans after neuropeptide ACTH 4-10. Exp Brain Res 1987;67:85-92.
5. Egleton RD, Davis TP: Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 1997;18:1431-1439.
6. Banks WA, Kastin AJ: Permeability of the blood-brain barrier to melanocortins. Peptides 1995;16:1157-1161.
7. Balin BJ, Broadwell RD, Salcman M, El-Kalliny M: Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 1986;251:260-280.
8. Riekkinen P, Legros JJ, Sennef C, Jolkkonen J, Smitz S, Soininen H: Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects. Peptides 1987;8:261-265.
9. Pietrowsky R, Strüben C, Mölle M, Fehm HL, Born J: Brain potential changes after intranasal vs. intravenous administration of vasopressin: Evidence for a direct nose-brain pathway for peptide effects in humans. Biol Psychiatry 1996;39:332-340.
10. Pietrowsky R, Thiemann A, Kern W, Fehm HL, Born J: A nose-brain pathway for psychotropic peptides: Evidence from a brain evoked potential study with cholecystokinin. Psychoneuroendocrinology 1996;21:559-572.
11. Kern W, Schiefer B, Schwarzenberg J, Stange EF, Born J, Fehm HL: Evidence for central nervous effects of corticotropin-releasing hormone on gastric acid secretion in humans. Neuroendocrinology 1997;65:291-298.
12. Born J, Unseld U, Pietrowsky R, Bickel U, Voigt KH, Fehm HL: Time course of ACTH 4-10 effects on human attention. Neuroendocrinology 1990;52:169-174.
13. De Kock S, De Kloet ER: Neurotrophic peptide ACTH-(4-10) permits glucocorticoid-facilitated retention of acquired immobility response of hypophysectomized rats. Eur J Pharmacol 1987;141:461-466.
14. Pigache RM, Rigter H: Effects of peptides related to ACTH on mood and vigilance in man. Front Horm Res 1981;8:193-207.
15. Perras B, Pannenborg H, Marshall L, Pietrowsky R, Born J, Fehm HL: Beneficial treatment of age-related sleep disturbances with prolonged intranasal vasopressin. J Clin Psychopharmacol, 1999;19:28-36.
16. Timsit-Berthier M, Mantanus H, Devos JE, Spiegel R: Action of lysine-vasopressin on human electroencephalographic activity; night sleep pattern, auditory evoked potential, contingent negative variation. Neuropsychobiology 1982;8:248-258.
17. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD: The cloning of genes that encode the melanocortin receptors. Science 1992;257: 1248-1251.
18. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, DelValle J, Yamada T: Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993;268: 8246-8250.
19. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, Cone RD: Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 1993;90:8856-8860.
20. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, DelValle J, Yamada T: Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993;268:15174-15179.
21. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD: Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994;8:1298-1308.
22. Chhajlani V, Muceniece R, Wikberg JES: Molecular cloning of a novel human melanocortin receptor. Biochem Biophys Res Commun 1993;195:866-873.
23. Desarnaud F, Labbe O, Eggerickx D, Vassart G, Parmentier M: Molecular cloning, functional expression and pharmacological characterization of a mouse melanocortin receptor gene. Biochem J 1994;299:367-373.
24. Gantz I, Shimoto Y, Konda Y, Miwa H, Dickinson CJ, Yamada T: Molecular cloning, expression, and characterization of a fifth melanocortin receptor. Biochem Biophys Res Commun 1994;200:1214-1220.
25. Schiöth HB, Muceniece R, Larsson M, Wikberg JES: The melanocortin 1,3,4, or 5 receptors do not have a binding epitope beyond the sequence of a-MSH. J Endocrinol 1997;155: 73-78.
26. Adan RAH, Cone RD, Burbach JPH, Gispen WH: Differential effects of melanocortin peptides on neural melanocortin receptors. Mol Pharmacol 1994;46:1182-1190.
27. van Rijzingen IM, Gispen WH, Spruijt BM: The ACTH(4-9) analog ORG 2766 and recovery after brain damage in animal models - A review. Behav Brain Res 1996;74:1-15.
28. Nockton R, Kastin AJ, Elder ST, Schally AV: Passive and active avoidance responses at two levels of shock after administration of melanocyte-stimulating hormone. Horm Behav 1972; 3:339-344.
29. Hillyard SA, Hink RF, Schwent VL, Picton TW: Electrical signs of selective attention in the human brain. Science 1973;182:177-182.
30. Greven HM, de Wied D: The active sequence of the ACTH molecule responsible for inhibition of the extinction of conditioned avoidance behavior in rats. Eur J Pharmacol 1967;2:14-16.
31. de Wied D: Effects of peptide hormones on behavior; in Ganong WF, Martini L (eds): Frontiers in Neuroendocrinology: London, Oxford University Press, 1969, pp 97-140.
32. Näätänen R: The role of attention in auditory information processing as revealed by event-related potentials and other brain measures of cognitive function. Behav Brain Sci 1990;13: 201-288.
33. Mölle M, Albrecht C, Marshall L, Fehm HL, Born J: ACTH widens the focus of attention in humans. A nonlinear EEG analysis. Psychosom Med 1997;59:497-502.
34. Born J, Fehm-Wolfsdorf G, Schiebe M, Birbaumer N, Fehm HL, Voigt KH: An ACTH 4-9 analog impairs selective attention in man. Life Sci 1985;36:2117-2125.
35. Oades RD, Dittmann-Balcar A: Mismatch negativity (MMN) is altered by directing attention. Neuroreport 1995;6:1187-1190.
36. Bickel U, Born J, Fehm HL, Distler M, Voigt KH: The behaviorally active peptide ACTH 4-10: Measurement in plasma and pharamacokinetics in man. Eur J Pharmacol 1988;35:371-377.
37. Hussain MA, Seetharam R, Wilk RR, Aungst BJ, Kettner CA: Nasal mucosal metabolism and absorption of pentapeptide enkephalin analogs having varying N-terminal amio acids. J Pharm Sci 1995;84:62-64.
38. Dua R, Zia H, Needham T: The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits. Int J Pharm 1997;147:233-242.
39. Born J, Kern W, Pietrowsky R, Sittig W, Fehm HL: Fragments of ACTH affect electrophysiological signs of controlled stimulus processing in humans. Psychopharmacology (Berl) 1989; 99:439-444.
40. Baker H, Spencer RF: Transneuronal transport of peroxidase-conjugated wheat germ agglutination (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res 1986;63:461-473.
41. Landfield PW, Baskin RK, Pitler TA: Brain aging correlates: Retardation by hormonal-pharmacological treatments. Science 1981;214: 581-584.
42. Born J, Fehm-Wolfsdorf G, Voigt KH, Fehm HL: Influences of ACTH 4-10 on event-related potentials reflecting attention in man. Physiol Behav 1987;39:83-87.
43. Mölle M, Pietrowsky R, Fehm HL, Born J: Regulation of human thought by neuropeptide ACTH 4-10: An analysis of the EEG's dimensional complexity. Neuroreport 1997;8:2715-2720.
44. Javitt DC, Doneshka P, Zylberman I, Ritter W, Vaughan HG Jr: Impairment of early cortical processing in schizophrenia: An event-related potential confirmation study. Biol Psychiatry 1993;33:513-519.
45. Catts SV, Shelley AM, Ward PB, Liebert B, McConaghy N, Andrews S, Michie PT: Brain potential evidence for an auditory sensory memory deficit in schizophrenia. Am J Psychiatry 1995;152:213-219.
46. Javitt DC, Steinschneider M, Schroeder CE, Arezzo JC: Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: Implications for schizophrenia. Proc Natl Acad Sci USA 1996;93:11962-11967.